Mitochondrial & Metabolic Peptides (MOTS-c, SS-31, GLP-1)

Navigation

Upward Index: 02 - Compounds & Molecules MOC | Literature Dossier: Mitochondrial & Metabolic Peptides (MOTS-c, SS-31, GLP-1) - References

---

1. Pharmacodynamics & Mechanism of Action

This sub-silo bridges mitochondrial-derived peptides (MDPs), inner-membrane cardiolipin stabilizers, and multi-receptor incretin agonists to remodel cellular bioenergetics, insulin sensitivity, and adipose partitioning.

• SS-31 (Elamipretide; D-Arg-Dmt-Lys-Phe-NH2): Cell-permeable aromatic-cationic tetrapeptide that concentrates $1,000\text{- to }5,000\text{-fold}$ inside the inner mitochondrial membrane (IMM) independent of mitochondrial membrane potential ($\Delta {\Psi }_m$).
  • Cardiolipin Electrostatic Binding: Selectively binds cardiolipin—the signature conical phospholipid of mitochondrial cristae. In aging and ischemia, cardiolipin undergoes peroxidation and converts Cytochrome c from an electron carrier into a destructive peroxidase, collapsing cristae curvature and opening the mitochondrial permeability transition pore (mPTP). SS-31 shields cardiolipin, restores Electron Transport Chain supercomplexes (I–III–IV), halts mitochondrial proton leak, and increases ATP synthesis ($P/O$ ratio) within $60\text{ minutes}$ in aged human and rodent muscle.
• MOTS-c (MRWQEMGYIFYPRKLR): 16-amino-acid Mitochondrial-Derived Peptide (MDP) encoded by a short open reading frame within the mitochondrial 12S rRNA gene; acts as an endogenous “mitokine” and exercise mimetic.
  • Folate–AICAR–AMPK Axis: Inhibits the folate-methionine cycle at de novo purine biosynthesis, causing a $20\text{-fold}$ accumulation of endogenous AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which directly activates AMPK and GLUT4 translocation in skeletal muscle.
  • Retrograde Mitonuclear Translocation: Under metabolic or oxidative stress, MOTS-c translocates from mitochondria into the cell nucleus in an AMPK-dependent manner, interacting with NRF2 and ARE transcription factors to regulate nuclear stress-response genes.
• Multi-Receptor Incretins (Semaglutide, Tirzepatide, Retatrutide) & 5-Amino-1MQ:
  • Semaglutide (GLP-1 RA): Mono-agonist at GLP-1R; enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic POMC/CART and brainstem nucleus tractus solitarius (NTS) satiety circuits while suppressing neuroinflammation.
  • Tirzepatide (GLP-1 / GIP Dual Agonist): Biased co-agonist with $5\times$ relative preference for GIPR over GLP-1R; GIP agonism in white adipose tissue enhances lipid buffering and insulin sensitivity while central GIP receptor activation suppresses GLP-1-induced nausea.
  • Retatrutide (LY3437943 — GLP-1 / GIP / Glucagon Triple Agonist): Adds Glucagon Receptor (GCGR) agonism, directly increasing resting energy expenditure, hepatic $\beta$-oxidation, and clearing hepatic steatosis (MASLD) by $>80\%$.
  • 5-Amino-1MQ: Small-molecule selective inhibitor of NNMT (Nicotinamide N-Methyltransferase) in adipocytes; prevents NNMT from wasting ${\text{NAD}}^{+}$ and $\text{SAMe}$ as 1-methylnicotinamide, raising intracellular ${\text{NAD}}^{+}\to$ SIRT1 activation.

---

2. Pharmacokinetics & Sequencing Architecture

Compound	Primary Target	Elimination $t_{1/2}$	Clinical Bioenergetic Role
SS-31 (Elamipretide)	Inner Mitochondrial Membrane Cardiolipin	$2\text{–}4\text{ hours}$ (plasma); prolonged IMM retention	Phase 1 Structural Repair: Rebuilds cristae and ETC supercomplexes before driving AMPK flux
MOTS-c	AICAR / AMPK & Nuclear NRF2	$30\text{–}60\text{ min}$ (plasma); $24\text{–}48\text{ h}$ AMPK activation	Phase 2 Metabolic Flux: Exercise-mimetic GLUT4 uptake, fatty acid oxidation, endurance
Semaglutide	GLP-1R	$\sim 165\text{ hours}$ ($\sim 7\text{ days}$)	Appetite suppression, glycemic control, cardiovascular/renal MACE reduction
Tirzepatide	GIPR + GLP-1R	$\sim 120\text{ hours}$ ($\sim 5\text{ days}$)	Superior insulin sensitization & visceral fat loss with lower GI side effects per % weight lost
Retatrutide	GIPR + GLP-1R + GCGR	$\sim 144\text{ hours}$ ($\sim 6\text{ days}$)	Adds hepatic GlucagonR thermogenesis & $-86\%$ liver fat clearance

---

3. Dosing, Cycling & Synergies

• Sequential Mitochondrial Protocol (SS-31 $\to$ MOTS-c):
  • Why Sequence: Driving AMPK/metabolic flux with MOTS-c in aged or damaged mitochondria with degraded cristae can increase ROS if the Electron Transport Chain is uncoupled.
  • Step 1 (Weeks 1–4 — Structural Cristae Repair): SS-31 (Elamipretide) $2\text{–}4\text{ mg/day}$ SubQ in the morning (with ${\text{NAD}}^{+}$ precursors / CoQ10).
  • Step 2 (Weeks 5–8 — AMPK & Mitokine Activation): MOTS-c $5\text{ mg}$ SubQ 2–3x/week administered $45\text{ min}$ prior to Zone 2 or HIIT aerobic training.
• Incretin Longevity / Micro-Dosing Protocol:
  • Clinical Obesity Dosing: Tirzepatide $2.5\text{–}15\text{ mg/week}$; Retatrutide $1\text{–}8\text{ mg/week}$.
  • Euglycemic / Anti-Inflammatory Micro-Dosing: Tirzepatide $0.5\text{–}1.25\text{ mg}$ twice weekly or Retatrutide $0.5\text{–}1.0\text{ mg/week}$, paired with mandatory resistance training + $1.6\text{–}2.2\text{ g/kg/day}$ protein + Creatine & Phosphocreatine System to prevent lean skeletal muscle loss.
• Contraindications & Biomarkers to Monitor:
  • Contraindications: GLP-1/GIP/GCGR agonists are contraindicated in personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), history of pancreatitis, or gastroparesis. MOTS-c consumes folate-cycle intermediates—always co-supplement with L-5-MTHF (Methylation & B-Complex) to prevent folate depletion.
  • Biomarkers: Fasting Insulin & HOMA-IR, HbA1c, Serum Lipase & Amylase, Calcitonin, DEXA Appendicular Lean Mass Index (ALMI), and Resting Heart Rate / HRV (GCGR/GLP-1R sinoatrial node receptors typically raise RHR by $+3\text{–}8\text{ bpm}$).

---

4. Key Scientific Evidence Summary

• MOTS-c Discovery & Exercise Capacity: Lee et al. (2015, Cell Metabolism) and Reynolds et al. (2021, Nature Communications) demonstrated that MOTS-c activates the AICAR-AMPK pathway, prevents age-dependent and high-fat-diet-induced insulin resistance, and doubles running capacity in aged mice while increasing human skeletal muscle MOTS-c expression by $11.9\text{-fold}$ during exercise.
• SS-31 Human In Vivo Mitochondrial ATP Restoration: Siegel et al. (2013) andKaraa et al. / Campbell et al. (2019) showed using ${}^{31}\text{P-MRS}$ that a single dose of SS-31 (Elamipretide) in aged humans and mice rapidly restores maximal mitochondrial ATP synthesis (${\text{ATP}}_{\max }$) and coupling ($P/O$) to young adult levels within 1 hour.
• Retatrutide Phase 2 NEJM Trial: Jastreboff et al. (2023) published in NEJM ($N=338$) that Retatrutide achieved a record $-24.2\%$ mean body weight reduction at 48 weeks (with $100\%$ of subjects on $8\text{–}12\text{ mg}$ losing $\ge 5\%$ weight and $>85\%$ resolution of MASLD liver fat).

See full study breakdowns in Mitochondrial & Metabolic Peptides (MOTS-c, SS-31, GLP-1) - References.